[go: up one dir, main page]

WO2014064534A3 - Injection needle, device, immunogenic compositions and method of use - Google Patents

Injection needle, device, immunogenic compositions and method of use Download PDF

Info

Publication number
WO2014064534A3
WO2014064534A3 PCT/IB2013/003034 IB2013003034W WO2014064534A3 WO 2014064534 A3 WO2014064534 A3 WO 2014064534A3 IB 2013003034 W IB2013003034 W IB 2013003034W WO 2014064534 A3 WO2014064534 A3 WO 2014064534A3
Authority
WO
WIPO (PCT)
Prior art keywords
needle
array
apertures
deliver
center
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/003034
Other languages
French (fr)
Other versions
WO2014064534A2 (en
Inventor
Gustaf AHLEN
Lars Frelin
Matti Sallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chrontech Pharma AB
Original Assignee
Chrontech Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrontech Pharma AB filed Critical Chrontech Pharma AB
Publication of WO2014064534A2 publication Critical patent/WO2014064534A2/en
Publication of WO2014064534A3 publication Critical patent/WO2014064534A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
    • A61M5/3291—Shafts with additional lateral openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
    • A61M5/3298—Needles arranged in parallel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles. The devices may be used to deliver immunogenic compositions such as those that illicit an immune response to the hepatitis c virus in naive or in chronically HCV infected individuals.
PCT/IB2013/003034 2012-10-05 2013-10-04 Injection needle, device, immunogenic compositions and method of use Ceased WO2014064534A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261710634P 2012-10-05 2012-10-05
US61/710,634 2012-10-05
US201361881391P 2013-09-23 2013-09-23
US61/881,391 2013-09-23

Publications (2)

Publication Number Publication Date
WO2014064534A2 WO2014064534A2 (en) 2014-05-01
WO2014064534A3 true WO2014064534A3 (en) 2014-11-06

Family

ID=50156793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003034 Ceased WO2014064534A2 (en) 2012-10-05 2013-10-04 Injection needle, device, immunogenic compositions and method of use

Country Status (1)

Country Link
WO (1) WO2014064534A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (en) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Modified nucleosides, nucleotides and nucleic acids and their application
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (en) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 Polynucleotides encoding low density lipoprotein receptor
JP2017000667A (en) * 2015-06-16 2017-01-05 国立大学法人三重大学 Needleless syringe and method for introducing DNA into injection target region using the same
WO2021016074A1 (en) * 2019-07-22 2021-01-28 The Trustees Of Indiana University Technologies for needles with microchannels
KR20220160042A (en) 2020-03-27 2022-12-05 스벤스카 박신파브리셴 프로둑숀 아베 Compositions and methods for treatment and prevention of coronavirus
WO2021225983A1 (en) * 2020-05-04 2021-11-11 Rutgers, The State University Of New Jersey System and method to use suction to enhance permeabilization and transfection of cells
CN115960244A (en) * 2021-09-14 2023-04-14 上海鸣大生物科技有限公司 Recombinant α-1,3-galactosyltransferase and its preparation method and application
US20230295244A1 (en) 2021-09-29 2023-09-21 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206919A1 (en) * 2000-08-17 2003-11-06 Matti Sallberg Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2011073796A2 (en) * 2009-12-16 2011-06-23 Chrontech Pharma Ab Injection needle and device

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5240855A (en) 1989-05-12 1993-08-31 Pioneer Hi-Bred International, Inc. Particle gun
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JP3368603B2 (en) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 Gene therapy treatment device
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
SE9401460D0 (en) 1994-04-28 1994-04-28 Ferring Ab Antigen / antibody specificity exhanger
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US6040137A (en) 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6019747A (en) 1997-10-21 2000-02-01 I-Flow Corporation Spring-actuated infusion syringe
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US7015040B2 (en) 1999-02-26 2006-03-21 Mirus Bio Corporation Intravascular delivery of nucleic acid
US6897068B2 (en) 1999-02-26 2005-05-24 Mirus Bio Corporation Polynucleotide complex delivery
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US7214369B2 (en) 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
EP1268759B1 (en) 2000-03-15 2006-09-27 Genexine Co., Ltd. Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
KR20080027973A (en) 2000-06-22 2008-03-28 와이어쓰 홀딩스 코포레이션 Cus-21 and IEL-12 as Adjuvant Combinations
US6440096B1 (en) 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6527216B2 (en) 2001-05-08 2003-03-04 Magnatech International Llp Electronic length control wire pay-off system and method
EP1585560A4 (en) 2002-07-26 2011-03-16 Mirus Bio Corp Delivery of molecules and complexes to mammalian cells in vivo
CN1756568A (en) 2002-10-09 2006-04-05 衣阿华中央卫生系统 Antitumor immunity using allogeneic tumor cells expressing α(1,3)-galactosyltransferase
WO2004048403A2 (en) 2002-11-26 2004-06-10 Tripep Ab Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
CN1747970A (en) 2003-02-06 2006-03-15 三肽公司 Antigen/antibody or ligand/receptor glycosylated specificity exchangers
FR2855758B1 (en) 2003-06-05 2005-07-22 Biomerieux Sa COMPOSITION COMPRISING NS3 / NS4 POLYPROTEIN AND HCV NS5B POLYPEPTIDE, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR USE IN THERAPEUTICS
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005011571A2 (en) 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US8445663B2 (en) 2009-02-02 2013-05-21 Chrontech Pharma Ab Compositions and methods that enhance an immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206919A1 (en) * 2000-08-17 2003-11-06 Matti Sallberg Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2011073796A2 (en) * 2009-12-16 2011-06-23 Chrontech Pharma Ab Injection needle and device

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRELIN L ET AL: "Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 10, 1 January 2003 (2003-01-01), pages 686 - 699, XP002285892, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3301933 *
GARCIA-NAVARRO R ET AL: "Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12", JOURNAL OF VIROLOGY, vol. 75, no. 19, October 2001 (2001-10-01), pages 9068 - 9076, XP002723966, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector

Also Published As

Publication number Publication date
WO2014064534A2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
WO2014064534A3 (en) Injection needle, device, immunogenic compositions and method of use
HK1197039A1 (en) Injection needle and device
WO2015106269A8 (en) Rapid action insulin formulations and pharmaceutical delivery systems
MX2018003306A (en) Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine.
MX2023000320A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion.
GT201400053A (en) VIRAL APPLICATION INHIBITORS
CA2875824C (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2015038818A3 (en) Liquid protein formulations containing viscosity-lowering agents
MX364396B (en) Modified poly(beta-amino ester)s for drug delivery.
WO2015095624A3 (en) Drug mixing and delivery system and method
BR112015018904A2 (en) access hole disinfection cleaner and needleless connector and antimicrobial protection cover
WO2012164390A3 (en) Auto-injector
HK1198869A1 (en) Combination treatments for hepatitis c
EP2471926A3 (en) Immunostimulatory oligodeoxynucleotides
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
IN2014KN02583A (en)
MX2013013800A (en) Immunostimulatory oligodeoxynucleotides.
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
SI2755973T1 (en) Substituted 4,5,6,7-tetrahydro-1h-pyrazolo(4,3-c)pyridines, their use as medicament, and pharmaceutical preparations comprising them
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
EP3248639A4 (en) Medical liquid-collection tip, liquid-collection nozzle, and injector set
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
EP3570916C0 (en) SAFETY SYRINGE WITH RETRACTABLE AND PRE-FILLED NEEDLE WITH TWO ACTIVE INGREDIENTS

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13831860

Country of ref document: EP

Kind code of ref document: A2